Anavex Life Sciences Corp (AVXL)

[falconer66a]

Correct. There will be no competition.

In any event, I don't believe that adevex is 2 - 73 [sic] is really in direct competition with aduhelm.

It’s just the opposite. After considering a) it’s gigantic price, b) it’s severe side effects, and c) it’s moderate to inconsequential suppression of symptoms, Aduhelm is in no direct competition with blarcamesine (Anavex 2-73).

Right now, there can be no real “competition.” Blarcamesine is not yet approved for treating Alzheimer’s. That won’t happen until Anavex gets FDA approval, late next year or sometime in 2023. By then, Aduhelm may be gone. Even for those who could afford the drug, its production of severe side effects, along with its very modest, and probably non-persisting treatment efficacies will doom it.

Up the road from me is the Cleveland Clinic, with a world-class neurology clinical program. The good doctors there have already proclaimed that Aduhelm will not be prescribed or used at the Cleveland Clinic. Side effects too severe; efficacies insufficient and non-enduring. At the Cleveland Clinic (and now, other medical centers) Aduhelm isn’t allowed in even the back door.

So, no, there is no “competition.” When it’s approved, blarcamesine will be the new Alzheimer’s standard of care (SOC) treatment. Nothing else, price-wise, by safety, or by enduring efficacy will be able to match it. Alzheimer’s therapies will be by one drug alone, blarcamesine. Good bye Aduhelm. Good bye Aricept. Welcome, blarcamesine.